Alteration of the spontaneous systemic autoimmune disease in (NZB x NZW)F1 mice by treatment with thimerosal (ethyl mercury)

被引:19
|
作者
Havarinasab, S. [1 ]
Hultman, P. [1 ]
机构
[1] Linkoping Univ, Dept Mol & Clin Med, SE-58185 Linkoping, Sweden
关键词
thimerosal; mice; autoimmunity; immune-complex; (NZB x NZW)F1 mice;
D O I
10.1016/j.taap.2005.12.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inorganic mercury may aggravate murine systemic autoimmune diseases which are either spontaneous (genetically determined) or induced by non-genetic mechanisms. Organic mercury species, the dominating form of mercury exposure in the human population, have not been examined in this respect. Therefore, ethyl mercury in the form of thimerosal, a preservative recently debated as a possible health hazard when present in vaccines, was administered in a dose of 0.156-5 mg/L drinking water to female (NZB x NZW)F1 (ZBWF1) mice. These mice develop an age-dependent spontaneous systemic autoimmune disease with high mortality primarily due to immune-complex (IC) glomerulonephritis. Five mg thimerosal/L drinking water (295 mu g Hg/kg body weight (bw)/day) for 7 weeks induced glomerular, mesangial and systemic vessel wall IC deposits and antinuclear antibodies (ANA) which were not present in the untreated controls. After 22-25 weeks, the higher doses of thimerosal had shifted the localization of the spontaneously developing renal glomerular IC deposits from the capillary wall position seen in controls to the mesangium. The altered localization was associated with less severe histological kidney damage, less proteinuria, and reduced mortality. The effect was dose-dependent, lower doses having no effect compared with the untreated controls. A different effect of thimerosal treatment was induction of renal and splenic vessel walls IC deposits. Renal vessel wall deposits occurred at a dose of 0.313-5 mg thimerosal/L (18-295 mu g Hg/kg bw/day), while splenic vessel wall deposits developed also in mice given the lowest dose of thimerosal, 0.156 mg/L (9 mu g Hg/kg bw/day). The latter dose is 3- and 15-fold lower than the dose of Hg required to induce vessel wall IC deposits in genetically susceptible H-2(s) mice by HgCl2 and thimerosal, respectively. Further studies on the exact conditions needed for induction of systemic IC deposits by low-dose organic mercurials in autoimmune-prone individuals, as well as the potential effect of these deposits on the vessel walls, are warranted. (c) 2005 Published by Elsevier Inc.
引用
收藏
页码:43 / 54
页数:12
相关论文
共 50 条
  • [1] Spontaneous autoimmune disease in (NZB X NZW)F1 mice is ameliorated by treatment with methimazole
    Mozes, E
    Zinger, H
    Kohn, LD
    Singer, DS
    JOURNAL OF CLINICAL IMMUNOLOGY, 1998, 18 (02) : 106 - 113
  • [2] Spontaneous Autoimmune Disease in (NZB × NZW)F1 Mice is Ameliorated by Treatment with Methimazole
    Edna Mozes
    Heidy Zinger
    Leonard D. Kohn
    Dinah S. Singer
    Journal of Clinical Immunology, 1998, 18 : 106 - 113
  • [3] CYCLOPHOSPHAMIDE TREATMENT OF KIDNEY DISEASE IN (NZB X NZW) F1 MICE
    RUSSELL, PJ
    HICKS, JD
    BURNET, FM
    LANCET, 1966, 1 (7450): : 1279 - &
  • [4] AUTOIMMUNE-DISEASE IN GERMFREE NZB-NZW F1 MICE
    UNNI, KK
    HOLLEY, KE
    TITUS, JL
    LABORATORY INVESTIGATION, 1974, 30 (03) : 406 - 406
  • [5] THE TREATMENT OF AUTOIMMUNE-DISEASE IN (NZB/NZW)F1 MICE WITH SYNGENEIC PHOTOMODULATED SPLENOCYTES
    LIN, RH
    WANG, LF
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1994, 39 (05) : 446 - 452
  • [7] Estrogen receptor-α deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice
    Bynote, K. K.
    Hackenberg, J. M.
    Korach, K. S.
    Lubahn, D. B.
    Lane, P. H.
    Gould, K. A.
    GENES AND IMMUNITY, 2008, 9 (02) : 137 - 152
  • [8] Acceleration of autoimmune disease in (NZB x NZW)F1 lupus prone mice by pristane.
    Morehead, K
    Cassafer, G
    Daikh, DI
    FASEB JOURNAL, 2002, 16 (05): : A1217 - A1217
  • [9] Leptin modulates autoimmune reactivity in (NZB x NZW)F1 lupus mice
    La Cava, A
    Ebling, FM
    Hahn, BH
    CLINICAL IMMUNOLOGY, 2005, 115 : S104 - S104
  • [10] Prevention of murine lupus disease in (NZB x NZW)F1 mice by sirolimus treatment
    Ramos-Barron, A.
    Pinera-Haces, C.
    Gomez-Alamillo, C.
    Santiuste-Torcida, I.
    Ruiz, J. C.
    Buelta-Carrillo, L.
    Merino, R.
    de Francisco, A. L. M.
    Arias, M.
    LUPUS, 2007, 16 (10) : 775 - 781